ABOUT THE EVENT
The 8th Annual Microbiome Connect: Europe 2022 is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.
As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.
Furthermore, separate tracks will be committed to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skin care applications.
Join us to hear from microbiome biotechs, pharma voices, investment bodies, consumer product brands and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
FIND OUT MORE
VIEW THE EVENT SCHEDULE for Microbiome Connect: Europe.
You will discover our leading industry speakers, as well as our new 2022 dedicated manufacturing stream.
Join our talented speakers such as:
Book Now to Attend Key Sessions Such As:
- The Need for Pharmaceutical Grade Probiotics - Staffan Stromberg, CEO, Infant Bacterial Therapeutics
- Developing Robust, Scalable & Reproducible Formulations and Processes for LBPs Entering Late Clinical Investigations and Reaching Market - Christophe Carite, CMC and Development Director, 4D Pharma and Bharat Dixit, VP Process and Manufacturing, Artugen
- Designing bacterial therapies to treat metabolic diseases and imbalances such as gout and chronic kidney disease - Rikke C Nielsen, CEO, Beo Therapeutics AG
- Systemic Approaches to Treating Acne - Lada Rasochova, Founder & CEO, Dermala
- Regulatory Complaint Microbiome Drugs: Meet the Regulators - Chrysi Sergaki, Interim Head of the Microbiome Section, MHRA and Magali Cordaillat-Simmons, Scientific and Regulatory Affairs Director, PRI
- ONCOBAX®-AK, A Game-Changer Live Biotherapeutic Product For Anticancer Immunotherapy - Romain Daillère, Head of Preclinical Research, Co-founder, EverImmune
- Live Topical Biotherapeutics For The Treatment Of Inflammatory Skin Disorders - Todd Krueger, President & CEO, AOBiome
- Development Of New (Multi-Target) Strategies For Microbiota Modulation As A Therapeutic Approach In Neurodegenerative Diseases - Jonathan Weiss, VP of Corporate and Business Development, Stellate Therapeutics
- CORAL™ Platform: Integration Of Consortium Design, Optimisation And Manufacturing For Microbiome Consortia Therapeutics Development With Multifactorial Mechanism-Of-Action - Sam Possemiers, Chief Executive Officer, MRM Health
- And Many More!
Will you be joining...
View full event schedule
2022 Speakers

Jean-Luc Marsat

Anders Kronström

Staffan Stromberg

Dr Jenny Bailey

Romaine Daillere
Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology. He currently acts as head of the preclinical research of EverImmune.

Luc Sterkman

Nigel Titford

Ghaith Bakdash PhD
Ghaith Bakdash is an immunologist with broad experience ranging from immune oncology to autoimmune disease and mucosal immunology. Following his PhD at the University of Amsterdam, his interest in translational research led him to a post-doc position at Radboud University Medical Cetner in Nijmegen, the Netherlands, where he contributed to the development of dendritic cell-based cancer vaccines. Later, he joined GSK as an investigator in the Respiratory Therapy Area, where he was participating in the development of new modalities to induce immune tolerance in the context of allergy and asthma. Currently, he is an Associate Director at Microbiotica, where he is leading the efforts of the Cell Biology team in live bacterial therapies development by elucidating the interactions between these therapeutic bacteria and host cells in the context of cancer and ulcerative colitis.

Sheri Meshner

Sophie Declomesnil

Chrysi Sergaki
Dr Chrysi Sergaki is the interim Head of Microbiome section at the National Institute for Biological Standards and Control (NIBSC), working on microbial interactions and how to utilise them for the benefit of human health.
At NIBSC, Chrysi is leading the microbiome standardisation program, with 18 World Health Organization (WHO) endorsed project to develop International Reference Reagents for the microbiome field as well as research projects investigating the role of the microbiome in gut health and disease. Prior to this, Chrysi has been working at NIBSC as scientist for two years leading research projects as well as the development of reference reagents for the DNA extraction of microbiome samples and will be evaluated as candidates for the first World Health Organization Whole Cell Reference Reagents for the microbiome.
Before joining the NIBSC in 2019, Chrysi completed her PhD at the University of Warwick, UK, researching microbial interactions in fungi and bacteria and their impact on the host by combining laboratory and bioinformatics approaches.

Henrik Bjørn Nielsen

Eric Van der Helm

Fabio Grassi

Jean de Gunzburg
Talk to me about… your research
I am the chief scientific officer at Da Volterra, a French biotechnology company, headquartered in Paris, France. Da Volterra is committed to the discovery and development of innovative approaches to prevent the deleterious consequences of antibiotic treatments on the intestinal microbiota, including the emergence and dissemination of antimicrobial resistance, as well as the occurrence of infections by opportunistic pathogens such as Clostridium difficile. Prior to that, I led an academic career as a cell biologist focusing on signal transduction and oncogenesis, ultimately leading a research laboratory at the Institut Curie in Paris.
Talk to me about…something people may not know about you
I was born in Canada, lived for most of my life in France, and am now based in the London. I am an avid off-piste skier, in the French and Swiss Alps. I particularly enjoy the slow hiking/skinning up the mountains which gives me time to appreciate the fabulous scenery, and to think in depth about new and arising matters, in particular in relation to my research.

Niall Hyland

Rikke Nielson

Robert JM Brummer MD PhD

Sam Possemiers

Vivek Lal

Morten Isaksen

Bharat Dixit

Frederic Elustondo

Gabriel Leventhal

Anna Kattel Ph.D
Anna is a third-year industrial PhD student at Tallinn University of Technology (TalTech). She is doing her research at the Center of Food and Fermentation Technologies (TFTAK).
The focus of her research is on next-generation probiotics and consortia manufacturing. She develops innovative ways how to manufacture stable consortia. That involves finding out how to control species ratios – support slower-growing species while avoiding the dominance of others. All that demands excellent knowledge of all the species. For that chemically defined media, isothermal microcalorimetry or bioreactors, metabolomics and consortia metabolic modelling is used. Anna has over five years of experience in the lab. Her previous studies involve acetoin microbial production and laboratory evolution.

Jonathan Weiss
Dr. Weiss completed his PhD at the NYU School of Medicine where he studied immune tolerance through the interactions of Treg and Th17 cells. Upon graduation he began working at Kadmon Pharmaceuticals as a scientist developing the first ROCK2 inhibitor. The drug, Rezurock (Belumosudil), was granted Orphan Drug and Breakthrough Therapy Designations by the FDA and bypassed a Phase III clinical trial. The drug was approved by the FDA in August 2021 for Chronic Graft Versus Host Disease (cGVHD). After completing his MBA, Dr. Weiss joined the Stellate Therapeutics team to help move their therapeutics programs towards the clinic.

Joseph Maxwell
Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.

Laurent Chesnel

Magali Cordaillat
Dr. Magali Cordaillat-Simmons earned her PhD in 2005 at the Université Paris V René Descartes, France, in Pharmacology, and her second Master’s degree in Pharmaceutical Regulatory Affairs at the Strasbourg Pharmacy School in 2014. Following her doctoral work with Pr. Ariel Gomez in pediatric nephrology at the University of Virginia from 2006 to 2009, Magali joined the newly-created Pharmabiotic Research Institute (PRI), which is an industrial-scientific Association dedicated to supporting the field in the development and registration of microbiome-based medicinal products for the European market. As Scientific and Regulatory Affairs Director, and in close collaboration with the PRI’s more than 80 industry members and academic partners, she oversees the organization’s EU-wide initiatives, which include EU-funded R&I projects, national and EU-level scientific advice request dossiers, and collaborative Task Group work on shared challenges for the field (CMC, standardization efforts, clinical design).

Paul Garofolo

Tomas de Wouters

Dr Chris Callewaert
Chris received his PhD from Ghent University in Belgium. He is now a postdoctoral research fellow in the Knight lab at the University of California, San Diego. He investigates body odor and the characteristics of the bacteria living in the armpits, skin, clothes, washing machines and homes. He is the first to undertake bacterial transplants to solve underarm body odour.

Christian Röhrig

Lada Rasochova

Shahram Lavasani
Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019.

Dr Yuri Martina

Todd Krueger

Trevor Steyn
Trevor Steyn is the CEO and founder of Esse Skincare. As an organic chemist his research has taken a broader approach to optimising skin health in the long term. Esse launched its first live probiotic product in February 2015 and has subsequently pioneered several new technologies in modulating the skin microbiome.

Amine Zorgani Ph.D

Chiara Heidi

Simone Guglielmetti

Eline Klaassens

Patrick Tripp

Isabelle de Cremoux

Kristin Wannerberger
Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.

Audrey Gueniche Ph.D
Audrey GUENICHE obtained her Pharmacist degree and her PhD degree in skin biology more than 23 years ago. She is an expert on immunology and microbiology. Her main expertise is on skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a senior clinical expert in LOREAL RESEARCH. She has a complete experience from the actives through vitro evaluations/ preclinical studies to clinical trials. Her passion is to always reinvent evaluation and find new fields of area in term of actives to promote.
She has published over 110 papers in peer-reviewed journals, 5 chapters in books, 2 specials issues in journal where she was the invited editor. She presented in over 80 international congresses and additionally she was personally invited to give more than 35 keynote lectures.

Leo Lathi
Venue
Hotel Okura Amsterdam, Ferdinand Bolstraat 333, 1072 LH Amsterdam, Netherlands
Microbiome Connect invites you to join us at Hotel Okura on the 6 - 7th July 2022.
Click here to view local hotels.
Founders Forum
The Microbiome Connect: Founders Forum is a business network, strictly for biotechs which encourages peer-to-peer networking and collaboration.
During Microbiome Connect, we invite CEO’s, Founders and Business Leaders to collaborate, brainstorm ideas, share pain and find solutions to the current challenges surrounding research, development, manufacture, regulation and investment.
The Founders Forum will guide each attendee through a series of group discussion with other biotech leaders to get straight to the heart of the issues at the top of their priority list.
If you are interested in being a part of the Founders Forum, make sure to click the Founders forum opt-in box when registering for the event.
REGISTER YOUR PLACE
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Early Bird Ends Friday 10th June
OUR MICROBIOME COMMUNITY

2022 SPONSORS
Gold Event Partner
Clinical Microbiomics
Website: www.clinical-microbiomics.com
At Clinical Microbiomics, we can offer custom tailored microbiome analysis ranging from pilot-projects to cohort studies with thousands of subjects, from 16S profiling to de-novo metagenomic characterization of different microbiomes, from simple group comparisons to ultra high-resolution phylogeny-based statistics, integrative systems biology and machine learning.
We offer a GCP compliant microbiome pipeline for clinical trials with microbiome endpoints and regularly support. Our Copenhagen-based laboratory is ISO17025 certified and we can offer microbiome services for a range of application areas, such as skin care & cosmetics, prebiotic & nutrition, probiotic & LBPs and animal health, where we can investigate a range of different sample types, including stool, skin, saliva, urine and respiratory.
Our team consists of highly experienced microbiome scientists and bioinformaticians, with extensive publication records in the microbiome field, and are experienced both in the laboratory and in developing bioinformatics and machine learning technologies.
Baseclear
Website: https://www.baseclear.com/
As genomics experts and through sustainable partnerships BaseClear offers consultancy and technological expertise to accelerate the understanding and use of microorganisms. BaseClear, located in the leading biomedical hotspot in Europe, offers a complete range of microbial genomics services, including metagenomics, microbiome analysis and microbial strain assessment for regulatory approval.
Biose Industrie
Website: https://www.biose.com/en/cdmo/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
Quay Pharma
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Microba
Website: https://microba.com/
Microba is a global microbiome company including a precision microbiome analysis service division leveraging superior sampling method, high-throughput sequencing, best-in-class profiler, and the most comprehensive genome reference database.
Combined with advanced analytics, AI expertise and biological knowledge, Microba offers end-to-end research support with robust microbiome analysis and data interpretation, enabling therapeutic, diagnostic discoveries and exploratory microbiome monitoring. Using its platform, Microba’s ongoing population study also provides the largest catalogue of metagenome and associated metadata for data mining, and microbiome associations discovery.
Event Partner
Bacthera
Website: https://www.bacthera.com/
Bacthera is a Danish/Swiss-based one-stop CDMO in the field of LBP’s, with the overall goal to enable the entire industry to further flourish by introducing industry changing innovations.
From small start-up’s to globally operating pharmaceutical companies, we support our clients developing analytical and manufacturing processes of their strains. With our long experience in handling bacteria in DS and DP production, we can offer tailor-made development and large-scale commercial solutions. Within our facilities, we can handle:
- Strictly and facultative anaerobes
- BSL1/2 categorized strains
- GMO’s
Our customers benefit from background technologies and GMP manufacturing know-how that originate from our mother companies Chr. Hansen & Lonza. In addition, Bacthera’s process expertise, enabling innovations and our world-class analytical services will contribute to our customer’s successful development of their LBP.
Bayer
Website: https://www.bayer.com/en/
Bayer is a recognized leader in the area of women’s healthcare, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide. Today, Bayer’s research and development efforts focus on finding new treatment options for menopause as well as gynecological diseases and includes several compounds in various stages of pre-clinical and clinical development. Together, these projects reflect the company’s approach to research, which prioritizes targets and pathways with the potential to alter the way that gynecological diseases are treated. Additionally, Bayer intends to provide 100 million women in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations.
COPAN
Website: https://www.copangroup.com/
Copan is dedicated to developing and providing high quality and cutting-edge biological sample collection products for infectious diseases, forensic, human genomics and environmental applications, along with automated workflow solutions.
To offer an efficient nucleic acid collection for microbiome analysis purposes, we specifically designed our new product SMART-eNAT®. Provided with the innovative post-collection activation system, SMART-eNAT® inhibits microbial growth and DNA degradation, ensuring safe transport for prolonged periods at ambient temperature and an unbiased microbiome profiling.
Today Copan is still eager to continue this innovation, providing quality products, customized services and prime solutions to improve the health and wellness of patients. Visit our booth to learn more about us!
DNA Genotek Inc.
Website: www.dnagenotek.com
DNA Genotek Inc. is a subsidiary of OraSure Technologies, Inc. working to provide high-quality microbial sample collection products and comprehensive services for sample processing, sequencing, and bioinformatic analysis. DNA Genotek’s OMNIgene product line immediately stabilizes microbiota samples at the point of collection, ensuring an unbiased ‘snapshot’ of the microbial community. Self-collection kits for stool, oral, skin, vaginal and animal sampling are available.
ProDigest
Website: www.prodigest.eu
ProDigest is a contract research provider with broad range of solutions for in vitro gastrointestinal simulation, both for the upper and the lower gastrointestinal tract, ranging from high throughput screening to in depth investigation of the mode of action and site of effect.
For example, we assist your product development by building up essential know-how in the field of gastrointestinal transit, bioavailability, digestion, metabolism, microbiome, immune modulation and efficacy of probiotics, prebiotics, functional ingredients, and pharmaceuticals, in relation to their fate and function in the body.
Our long-standing experience and expertise in studying the gastrointestinal processes at your service!
Phage Consultants
Website: https://phageconsultants.com/
Please visit our website for more information.CosmosID
Website: www.cosmosid.com
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for research and development.
CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision. Results can be accessed via CosmosID-HUB, a user-friendly and interactive software for comparative analysis of microbiome data, complete with dynamic charts, visualizations, and statistics.
Innovation Partners
Biomes
BIOMES is a genomic deep-tech startup which seeks to improve the individual life by precision nutrition & health prevention. BIOMES is combining state-of-the-art high-throughput sequencing with machine learning algorithms to find significant patterns combining microbiota profiles and lifestyle & health phenotypes. With BIOMES first retail product, the INTEST.pro gut microbiome analysis, retails customers can discover their intestinal flora and life-changing effects by re-balancing their microbiome via personalized nutrition and analytic-based supplements. BIOMES provides high-throughput genomic lab services and deep data analysis solutions for industrial & academic partners leveraging a worldwide unique meta data-pool, containing of more than 31,000 biological microbiota profiles associated to individual health and lifestyle data.
TNO
Website: https://www.tno.nl/en/
TNO is a research and technology innovation institute which drives biomedical, technological and social innovations in collaboration with knowledge institutes, industrial partners and government authorities. Multidisciplinary teams of top scientists and technical experts enable us to model, mimic and measure health and disease risk. We connect experimental and clinical studies with innovative technologies to identify new biomarkers for health and disease, as well as substantiate the health benefit of compounds. Together, we can make a contribution to future health. Visit: https://www.tno.nl/en/ for more info
Media Partners
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Website: https://www.escmid.org/membership_organisation/about_escmid/
Since its founding in 1983, ESCMID has evolved to become Europe’s leading society in clinical microbiology and infectious diseases with members from all European countries and all continents. For more than 30 years, ESCMID has been an influential component in the professional lives of microbiologists and infectious disease specialists and now reaches more than 8,500 individual and 30,000 affiliated members around the world. ESCMID, based in Basel, Switzerland, welcomes new colleagues from all nations.
Microbiome Research Reports
Website: https://oaepublish.com/mrr
Microbiome Research Reports (MRR) is an international peer-reviewed, open access journal officially launched in July 2021. The scope of the journal includes investigations of microbiomes present in one or various body compartments of human beings or other animals. Surveys on the establishment of microbial communities as well as on microbe-microbe interactions and microbe-host communication will be considered for publication.
Pharma Journalist
Website: www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
National Biofilms Innovation Cenre
Website: https://www.biofilms.ac.uk/
The National Biofilms Innovation Centre is an Innovation Knowledge Centre (IKC), funded jointly by BBSRC, Innovate UK and the Hartree Centre.
TESTIMONIALS
Partner With Us
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact [email protected].
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
REGISTER YOUR INTEREST
Fill in your details below to get in touch with our Sanctions & Export Controls Webinar team.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.